Assessment superseded
Fisetin senolytic showed safety signals in Phase I/II osteoarthritis trial; efficacy unclear
This Phase I/II randomized, double-blind, placebo-controlled trial tested the senolytic drug fisetin in patients with mild to moderate osteoarthritis. The abstract reports testing for safety and efficacy, but does not present actual efficacy results or sample size details.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 19, 2024 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Osteoarthritis-related articular cartilage degeneration
- Effect size
- —
- Significance
- Not reported
- Journal
- Steadman Philippon Research Institute
- Published
- Sep 19, 2024
Sources
Primary source
- Steadman Philippon Research Institute ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.